StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Coherus Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Coherus Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $101.21M, up 8.3% year over year. For fiscal 2025 it was $108.89M, up 18.6% from the year before. Over ten years it grew -6.5% a year on average. The highest annual figure on record is $363.11M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$108.89M+18.6%
FY2024Dec 31, 2024$91.83M-16.1%
FY2023Dec 31, 2023$109.44M-45.1%
FY2022Dec 31, 2022$199.36M-45.1%
FY2021Dec 31, 2021$363.11M+154.3%
FY2020Dec 31, 2020$142.76M+51.6%
FY2019Dec 31, 2019$94.19M-14.6%
FY2018Dec 31, 2018$110.24M-32.1%
FY2017Dec 31, 2017$162.39M-36.2%
FY2016Dec 31, 2016$254.44M+19.4%
FY2015Dec 31, 2015$213.06M+172.4%
FY2014Dec 31, 2014$78.22M+150.1%
FY2013Dec 31, 2013$31.28M-10.3%
FY2012Dec 31, 2012$34.89M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$21.44M-18.5%
Q1 FY2026Mar 31, 2026$21.54M-11.5%
Q4 FY2025Dec 31, 2025$30.97M+49.2%
Q3 FY2025Sep 30, 2025$27.25M+23.6%
Q2 FY2025Jun 30, 2025$26.31M+27.7%
Q1 FY2025Mar 31, 2025$24.36M-14.3%
Q4 FY2024Dec 31, 2024$20.76M-21.3%
Q3 FY2024Sep 30, 2024$22.05M-14.0%
Q2 FY2024Jun 30, 2024$20.60M-11.5%
Q1 FY2024Mar 31, 2024$28.42M-16.8%
Q4 FY2023Dec 31, 2023$26.37M-9.1%
Q3 FY2023Sep 30, 2023$25.65M-44.0%
Q2 FY2023Jun 30, 2023$23.27M-44.1%
Q1 FY2023Mar 31, 2023$34.15M-58.8%
Q4 FY2022Dec 31, 2022$29.02M-42.8%
Q3 FY2022Sep 30, 2022$45.81M-15.3%
Q2 FY2022Jun 30, 2022$41.61M-24.0%
Q1 FY2022Mar 31, 2022$82.92M-59.3%
Q4 FY2021Dec 31, 2021$50.76M+13.7%
Q3 FY2021Sep 30, 2021$54.09M+39.2%
Q2 FY2021Jun 30, 2021$54.77M+109.2%
Q1 FY2021Mar 31, 2021$203.49M+514.6%
Q4 FY2020Dec 31, 2020$44.63M+27.7%
Q3 FY2020Sep 30, 2020$38.85M+80.1%
Q2 FY2020Jun 30, 2020$26.17M+38.6%
Q1 FY2020Mar 31, 2020$33.11M+76.2%
Q4 FY2019Dec 31, 2019$34.95M+31.1%
Q3 FY2019Sep 30, 2019$21.57M-31.8%
Q2 FY2019Jun 30, 2019$18.88M-28.8%
Q1 FY2019Mar 31, 2019$18.79M-26.2%
Q4 FY2018Dec 31, 2018$26.66M-15.3%
Q3 FY2018Sep 30, 2018$31.60M-25.9%
Q2 FY2018Jun 30, 2018$26.52M-23.1%
Q1 FY2018Mar 31, 2018$25.46M-52.7%
Q4 FY2017Dec 31, 2017$31.49M-46.6%
Q3 FY2017Sep 30, 2017$42.63M-34.0%
Q2 FY2017Jun 30, 2017$34.50M–
Q1 FY2017Mar 31, 2017$53.78M–
Q4 FY2016Dec 31, 2016$59.01M–
Q3 FY2016Sep 30, 2016$64.57M–

More Coherus Oncology figures

See a number that looks wrong?